Optimizing the Management of Patients with Advanced Non-Melanoma Skin Cancers in Community-based Dermatology, Oncology, and Dermato-oncology Practices

Reference	Link
Basset-Seguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. *Eur J Cancer*. 2017;86:334-348. doi:10.1016/j.ejca.2017.08.022	https://pubmed.ncbi.nlm.nih.gov/29073584/
Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer.* 2021;9(6):e002435. doi:10.1136/jitc-2021-002435	https://pubmed.ncbi.nlm.nih.gov/34172516/
Conforti C, Corneli P, Harwood C, Zalaudek I. Evolving role of systemic therapies in non-melanoma skin cancer. *Clin Oncol (R Coll Radiol).* 2019; 31(11):759-768. doi:10.1016/j.clon.2019.08.011	https://pubmed.ncbi.nlm.nih.gov/31522944/
Dummer R, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. *Br J Dermatol*. 2020;182(6):1369-1378. doi:10.1111/bjd.18552	https://pubmed.ncbi.nlm.nih.gov/31545507/
García-Sancha N, Corchado-Cobos R, Bellido-Hernandez L, et al. Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma. *Cancers (Basel).* 2021;13(20):5134. doi:10.3390/cancers13205134	https://pubmed.ncbi.nlm.nih.gov/34680282/
Grob JJ, Gaudy-Marquest C, Guminski A, et al. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. *J Eur Acad Dermatol Venereol*. 2021;35(11):2149-2153. doi:10.1111/jdv.17467	https://pubmed.ncbi.nlm.nih.gov/34424580/
Grob JJ, Gonzalez R, Basset-Sequin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase II trial (KEYNOTE-629). *J Clin Oncol.* 2020;38(25):2916-2925. doi:10.1200/JCO.19.03054	https://pubmed.ncbi.nlm.nih.gov/32673170/
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl 4):iv119-iv142. doi:10.1093/annonc/mdx225	https://pubmed.ncbi.nlm.nih.gov/28881921/

Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial. *Ann Oncol*. 2021;32(10):1276-1285. doi:10.1016/j.annonc.2021.07.008	https://pubmed.ncbi.nlm.nih.gov/34293460/
Maubec E, Boubaya M, Petrow P, et al. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. *J Clin Oncol*. 2020;38(26):3051-3061. doi:10.1200/JCO.19.03357	https://pubmed.ncbi.nlm.nih.gov/32730186/
Migden M, Farberg AS, Dummer R, Squittieri N, Hanke CW. *J Drugs Dermatol*. A review of Hedgehog inhibitors sonidegib and vismodegib for treatment of advanced basal cell carcinoma. 2021;20(2):156-165. doi:10.36849/JDD.5657	https://pubmed.ncbi.nlm.nih.gov/33538567/
Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. *Lancet Oncol*. 2015;16(6):716-728. doi:10.1016/S1470-2045(15)70100-2	https://pubmed.ncbi.nlm.nih.gov/25981810/
Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial. *Lancet Oncol.* 2020;21(2):294-305. doi:10.1016/S1470-2045(19)30728-4	https://pubmed.ncbi.nlm.nih.gov/31952975/
Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *N Eng J Med*. 2018;379(4):341-351. doi:10.1056/NEJMoa1805131	https://pubmed.ncbi.nlm.nih.gov/29863979/
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. V2.2022. March 24, 2022.	https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Management of Immunotherapy-Related Toxicities. V1.2022. February 28, 2022.	https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Squamous Cell Skin Cancer. V2.2022. May 2, 2022.	https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*. 2018;378(2):158-168. doi:10.1056/NEJMra1703481	https://pubmed.ncbi.nlm.nih.gov/29320654/

Roper E, Lum T, Palme CE, et al. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. *Pathology*. 2017;49(5):499-505. doi:10.1016/j.pathol.2017.04.004	https://www.sciencedirect.com/science/article/abs/pii/S0031302517300715
Schmults CD, Karia PS, Carter JB, Han J, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: A 10-year, single-institution cohort study. *JAMA Dermatol*. 2013;149(5):541-547. doi:10.1001/jamadermatol.2013.2139	https://pubmed.ncbi.nlm.nih.gov/23677079/
Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. *BMC Cancer*. 2017;17(1):332. doi:10.1186/s12885-017-3286-5	https://pubmed.ncbi.nlm.nih.gov/28511673/
Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med*. 2012;366(23):2171-2179. doi:10.1056/NEJMoa1113713	https://pubmed.ncbi.nlm.nih.gov/22670903/
Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment *Eur J Cancer*. 2020;128:83-102. doi:10.1016/j.ejca.2020.01.008	https://pubmed.ncbi.nlm.nih.gov/32113942/
Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. *Lancet Oncol*. 2021;22(6):848-857. doi:10.1016/S1470-2045(21)00126-1	https://pubmed.ncbi.nlm.nih.gov/34000246/
Villani A, Fabbrocini G, Costa C, Scalvenzi M. Sonidegib: Safety and efficacy in treatment of advanced basal cell carcinoma. *Dermatol Ther (Heidelb)*. 2020;10(3):401-412. doi:10.1007/s13555-020-00378-8	https://pubmed.ncbi.nlm.nih.gov/32297221/